Amgen 2004 Annual Report Download - page 13

Download and view the complete annual report

Please find page 13 of the 2004 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 38

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38

General medicine
Molecule Disease/condition
Aranesp® Anemia of chronic renal disease
Aranesp® Anemia in congestive heart failure
EPOGEN® Anemia of end-stage renal disease
(Epoetin alfa)
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Metabolic disorders
Molecule Disease/condition
11ß-HSD1 Metabolic syndrome
AMG 076 Obesity
AMG 131 Type 2 diabetes
AMG 162 Postmenopausal osteoporosis
Leptin Lipodystrophy
(abnormal fat changes)
Leptin Hypothalamic amenorrhea
(absence of menstruation)
Sensipar® Secondary hyperparathyroidism
(cinacalcet HCl) in end-stage renal disease
Sensipar® Hypercalcemia of
parathyroid carcinoma
Sensipar® Primary hyperparathyroidism
Sensipar® Secondary hyperparathyroidism
in chronic renal insuffi ciency
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Preclinical studies collect data to show that
a molecule is reasonably safe for use in initial
small-scale clinical trials.
Phase 1 clinical trials investigate safety and
proper dose ranges of a product candidate in
a small number of human subjects.
Phase 2 clinical trials investigate side effect
profi les and effi cacy of a product candidate
in a large number of patients who have the
disease or condition under study.
Phase 3 clinical trials investigate the safety
and effi cacy of a product candidate in a large
number of patients who have the disease or
condition under study.
These tables are current as of February 3, 2005, and show the status of
selected clinical and preclinical molecules in Amgen’s product pipeline.
Amgen’s product pipeline will change over time as molecules move through
the drug development process, including progressing to market or failing
in clinical trials, due to the nature of the development process. These
tables contain forward-looking statements that involve signifi cant risks
and uncertainties, including those discussed in Amgen’s most recent Form
10-K and in Amgen’s periodic reports on Form 10-Q and Form 8-K, and
actual results may vary materially. Amgen is providing this information
as of the date above and does not undertake any obligation to update
any forward-looking statements contained in this table as a result of new
information, future events or otherwise.
For more information on Amgen’s product pipeline,
please visit www.amgen.com.
For important safety information about Amgen’s
marketed products, please visit www.amgen.com for
links to the product Web sites.
Neuroscience
Molecule Disease/condition
AMG 403 Pain
AMG 517 Pain
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Amgen 2004 Annual Report page 11